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 33.1  Introduction 
 Neovascularization is a hallmark of several eye diseases leading to visual impair-
ment, and its epidemiological impact is substantial ( Lee et al.  1998 ) . In retinal 
degenerative disease models, neovascularization is the process by which the choroid 
and/or retina become inﬁ ltrated with new blood vessels. In retinal neovasculariza-
tion (RNV), sprouting retinal vessels penetrate the inner limiting membrane (ILM) 
and grow into the vitreous, and in some cases, grow through the avascular outer 
retina into the subretinal space (Campochiaro  2000 ) . Numerous clinical and 
 R. M.  Yetemian 
 Mary D. Allen Laboratory for Vision Research ,  Doheny Eye Institute, Keck School of Medicine, 
University of Southern California ,  Los Angeles ,  CA  90033-9224 ,  USA 
 Department of Ophthalmology ,  Keck School of Medicine of the University 
of Southern California ,  Los Angeles ,  CA  90033-9224 ,  USA 
Regulatory Affairs, Abbott Medical Optics, Inc., Santa Ana, CA 92705, USA
 C. M.  Craft (*)
 Mary D. Allen Laboratory for Vision Research ,  Doheny Eye Institute, Keck School of Medicine, 
University of Southern California ,  Los Angeles ,  CA  90033-9224 ,  USA 
 Department of Ophthalmology ,  Keck School of Medicine of the University of Southern 
California ,  Los Angeles ,  CA  90033-9224 ,  USA 
 Department of Cell & Neurobiology ,  Keck School of Medicine of the University of Southern 
California ,  Los Angeles ,  CA  90033-9224 ,  USA 
e-mail:  ccraft@usc.edu 
 Chapter 33 
 Retinal Neovascular Disorders: Mouse Models 
for Drug Development Studies 
 Rosanne  M.  Yetemian and  Cheryl  M.  Craft  
M.M. LaVail et al. (eds.), Retinal Degenerative Diseases, Advances in Experimental 
Medicine and Biology 723, DOI 10.1007/978-1-4614-0631-0_33, 
© Springer Science+Business Media, LLC 2012
254 R.M. Yetemian and C.M. Craft
 experimental observations indicate that ischemia (or hypoxia) is the driving force 
behind RNV (Michaelson and Steedman  1949 ) . Occlusion of retinal vessels leading 
to ischemia is a feature of diseases with RNV, including diabetic retinopathy (DR) 
and retinopathy of prematurity (ROP) (Campochiaro  2000 ) . 
 Choroidal neovascularization (CNV) is characterized by new blood vessels emanat-
ing from the choroid into the subretinal pigment epithelium, subretinal space, or both 
(Qazi et al.  2009 ) .This leads to the formation of neovascular membranes, which include 
vascular endothelial cells, retinal pigment epithelial (RPE) cells, and macrophages 
(Das and McGuire  2003 ) . Vascular endothelial growth factor (VEGF) and platelet-
derived growth factor (PDGF) are essential mediators in the development of CNV, 
which is the primary form of neovascularization in age-related macular degeneration 
(AMD) patients. Although multiple factors have been implicated in the development of 
neovascularization, future studies are warranted in the identiﬁ cation of novel treatment 
strategies. To better understand the current mouse models available to study RNV 
and CNV, a brief review of the retinal diseases characterized by neovascularization is 
examined below. 
 33.2  Proliferative Diabetic Retinopathy 
 The most common cause of blindness among Americans between the ages of 20–74 
is DR. This disorder can be classiﬁ ed as either nonproliferative or proliferative. 
Whereas nonproliferative DR is characterized by venous dilation, retinal hemor-
rhage, and microaneurysms, proliferative DR is characterized by abnormal new 
 vessel and ﬁ brous tissue proliferation on the surface of the retina (Lee et al.  1998 ) . 
Ischemia of the inner retinal layers causes the release of VEGF, stimulating new 
blood vessel formation locally and in other regions of the eye (Besirli and Johnson 
 2009 ) . For diabetics, RNV is the major contributor to blindness, and treatment of 
neovascularization can reduce severe visual loss from 50% to approximately 5% per 
year (Lee et al.  1998 ) . 
 33.3  Retinopathy of Prematurity 
 ROP is characterized by RNV that eventually affects the vitreous, causes retinal detach-
ment, and inevitable blindness in premature infants ( Lee et al.  1998 ) . ROP, like DR, is 
primarily characterized by RNV and less by CNV. The disease can progress in two 
phases: (1) delayed retinal vascular growth after birth and partial regression of existing 
vessels followed by (2) hypoxia-induced pathological vessel growth (Chen and Smith 
 2007 ) . ROP develops through conditions of excessive hyperoxia and hypoxia leading 
to deregulation of VEGF expression. Serum insulin-like growth factor 1 (IGF-1) has 
also shown to directly correlate with the severity of ROP in the clinic. Taken together, 
the pathophysiology of ROP is similar to that of other retinal disease with RNV. 
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 33.4  Age-Related Macular Degeneration 
 A multifactorial cause of photoreceptor degeneration, AMD accounts for more than 
half of all blindness and visual impairment in developed countries primarily affect-
ing individuals over 60 (Ting et al.  2009 ) . Patients with AMD are categorized as 
having nonexudative (dry) or exudative (wet) stage forms of the disease. Dry AMD 
patients exhibit large, poorly demarcated drusen and RPE abnormalities. Wet AMD 
is characterized by local regions of RPE atrophy and growth of new blood vessels 
from the choroid that penetrate Bruch’s membrane and enter the retina where they 
can leak and cause damage. Genetic association studies on AMD patients identiﬁ ed 
Complement Factor H (CFH) and Age-related Maculopathy Susceptibility 2 
(ARMS) genes as contributors to AMD (Wright et al.  2010 ), with the effect sizes of 
these two susceptibility alleles unusually large by the standard of most complex 
traits. Current successful therapeutic strategies for treating AMD and improving 
visual quality include the use of anti-VEGF medicines. 
 33.5  Genetic Mouse Models for Neovascularization 
 The distinction between RNV and CNV in mouse models is important in that they 
are used to determine the type of disease for which they are most appropriate. For 
example, DR and ROP are both primarily characterized by RNV, and AMD, which 
may also be associated with RNV, exhibits CNV as the primary mechanism for 
neovascularization in the eye. 
 Transgenic mouse models for RNV provide an adequate resource for the charac-
terization of this phenomenon. One example is the  rho / VEGF transgenic mouse, 
which develops retinal and subretinal neovascularization (SRN) as a consequence 
of VEGF expression driven by the rhodopsin promoter. This model is a close repre-
sentation to patients with retinal angiomatous proliferation (RAP) (Miller  1997 ) . 
The development of VEGF 165 overexpressing transgenic mice driven by the trun-
cated rhodopsin promoter developed phenotypes ranging from mild to severe RNV 
and are also used in RNV studies (Miller  1997 ) . 
 The reverse tetracycline transactivator (rtTA) inducible promoter system coupled 
with the rhodopsin ( rho / rtTa-TRE / VEGF ) or interphotoreceptor retinoid-binding 
protein (IRBP) promoter ( IRBP / rtTA-TRE / VEGF ) has been used to control the onset 
of VEGF expression in the retina (Grossniklaus et al.  2010 ) . The addition of doxy-
cycline in these mice activates the expression levels of VEGF, and subsequently 
causes extensive RNV. In comparison to  rho / VEGF mice, these transgenic models 
are associated with total retinal detachment and higher ocular levels of VEGF 
mRNA and protein (Ohno-Matsui et al.  2002 ) . 
 A recently identiﬁ ed knockout mouse that also exhibits RNV is the  Nrl −/− Grk1 −/− 
mouse. The neural retina leucine zipper knockout ( Nrl −/− ), which lacks the transcrip-
tion factor responsible for normal rod photoreceptor development, leads to a retinal 
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phenotype with all cone photoreceptors that include an enhanced number of S-cones 
and a normal number of M-cones. The double knockout that  lacks the G-protein-
coupled receptor kinase 1 gene ( Nrl −/− Grk1 −/− ) involved in phototransduction recovery 
exhibits a light independent age-related degeneration (Zhu et al.  2003,  2006 ) . 
These mice exhibit an RNV phenotype similar to RAP and retinal vascularization 
that is ﬁ rst observed at 1 month and is mediated by the inﬂ ammatory response 
(Yetemian et al.  2010 ; Yetemian  2010 ) . 
 Relevant models of CNV can be found in transgenic knockout mice where CNV 
is a phenotypic distinction. One such model is the monocyte chemoattractant pro-
tein-1 (Ccl2) or its receptor CC-chemokine receptor-2 (Ccr2) deﬁ cient mouse, 
which are both current models for AMD (Ambati et al.  2003 ) . These transgenic 
mice lacking either Ccl2 or Ccr2 fail to recruit macrophages to the RPE or Bruch’s 
membrane, thereby allowing the accumulation of complement factor C5a and IgG, 
both of which induce VEGF production (Ambati et al.  2003 ) . 
 Other transgenic knockout mice that exhibit a CNV phenotype include mice that 
overexpress Apolipoprotein E (ApoE) that were fed a high fat diet and developed AMD 
like lesions (Malek et al.  2005 ) . Disruption of ceruloplasmin and hephaestin in mice 
causes iron overload and subsequent AMD-like changes. These mice develop RPE 
abnormalities and photoreceptor degeneration (Hahn et al.  2004 ) . Knockout mice for 
the very low density lipoprotein receptor gene (Vldlr TM1Her ) develop new blood vessels 
in the outer plexiform layer (OPL) of the retina as well as choroidal anastomoses by 
3 months (Heckenlively et al.  2003 ) . The transgenic mouse line (mcd/mcd) exhibits 
features associated with geographic atrophy and AMD. The mcd/mcd mice express 
a mutated form of cathepsin D that is enzymatically inactive, thereby impairing photo-
receptor outer segment phagocytosis by RPE cells (Rakoczy et al.  2002 ). Also, the 
Cu, Zn superoxide dismutase-deﬁ cient mouse ( Sod −/− ) has been shown to exhibit 
fundus and histological evidence of CNV in approximately 10% of  Sod −/− mice. 
 Another model for neovascularization similar to AMD is the spontaneous auto-
somal semidominant mouse mutation Belly spot and tail (Bst), which arose in the 
C57/Bl6J inbred strain at the Jackson Laboratory ( Smith et al.  1999 ) . The mutation 
was mapped to chromosome 16, 1.9 ± 1.1 cM from  D16Mit168 , and these mice have 
late closure of the optic ﬁ ssure, delayed retinal differentiation, decreased number of 
retinal ganglion cells, and coloboma of the optic nerve and retina (Smith et al.  1999 ) . 
A highly variable phenotype, aging  Bst + mice were found to have SRN. SRN begins 
in the choroid with vascular invasion through Bruch’s membrane into the subretinal 
space, and can lead to CNV in the form of subretinal hemorrhage that may undergo 
ﬁ brosis and cause more retinal damage (Smith et al.  1999 ) 
 33.6  Nongenetic Models for Neovascularization 
 Animal models for the study of RNV include hypoxia-induced, vascular occlusion, 
and intraocular injection of pro-angiogenic molecules. Hypoxia-induced models 
have been developed in several species and is performed by exposing mice to hyper-
oxia, then placing them in normoxic conditions, causing an ischemic situation that 
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initiates rapid abnormal neovascularization. This model has proven to delineate the 
molecular changes in neovascular eye disease and directly correlates to ROP (Ashton 
 1966 ; Chen and Smith  2007 ) . Occlusion of retinal veins by laser photocoagulation 
or photodynamic therapy has also been used in RNV studies (Ham et al.  1997 ) . 
 Animal models for nongenetically induced CNV include laser and surgically 
induced models. Experimental laser-induced mice were created using spot treatments 
from a krypton laser to create photocoagulation injuries to Bruch’s membrane (Ryan 
 1979 ; Tobe et al.  1998 ) . The laser-induced model is currently well established and 
is also used in preclinical trials for the study of anti-angiogenic drugs. Although the 
physical insult to Bruch’s membrane differs from the long-term chronic conditions 
that occur in human AMD, the models closely mimic natural cellular responses that 
occur in human CNV. Surgically induced forms of CNV are also currently in practice 
and are done primarily by the injection of synthetic peptides, viral vectors containing 
VEGF, and inert synthetic materials (Grossniklaus et al.  2010 ) . 
 33.7  Use of Mouse Models for Neovascularization 
in Preclinical Drug Testing 
 The discovery that VEGF plays a signiﬁ cant role in neovascularization spurred the 
development of several anti-VEGF pharmacological treatments such as Bevacizumab 
(Avastin), Ranizumab (Lucentis), (Genentech, Inc.), and Pegaptanib (Macugen) 
(Eyetech, Inc.). Bevacizumab (BVZ) is a full-length humanized monoclonal anti-
body that binds all isoforms of VEGF-A, Ranizumab (RBZ) is the 48 kDa form of 
BVZ, and Pegaptanib is a 28-base ribonucleic acid aptamer that binds to VEGF 165 . 
All are FDA approved, and the extensive preclinical studies for each involved the 
use of some of the mouse models discussed above. A study by Katsuaki et al. 
compared the effects of intraocular RBZ and BVZ injections using  rho / VEGF and 
doxycycline-treated  Tet / opsin / VEGF mice to demonstrate not only safety but also 
efﬁ cacy in suppression of SRN (Katsuaki et al.  2009 ) . A study funded by Eyetech, 
Inc. used a murine model of ROP in their  preclinical testing for Pegaptanib, among 
several other animal models for RNV ( Eyetech Study Group  2002 ). It is apparent 
from the preclinical testing conducted on these three currently marketed treatments 
for AMD that the mouse models utilized were inﬂ uential in the development of 
these drugs and will continue to be utilized during the development of future treat-
ments for neovascularization. 
 33.8  Conclusion 
 Despite their similarities in structure and function, the retinas of humans and mice 
are quite unique and do present challenges when compared. Mice, for example, have 
only two opsin expressing cones when compared to humans and lack a deﬁ ned 
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macula. Nevertheless, they have similar morphology and neuronal structures that are 
extremely comparable to the human retina and are extensively used in many disease 
studies. DR, ROP, and AMD are the leading forms of retinal dystrophy in the aging 
human population, and mouse models are becoming increasingly useful in identifying 
causative mechanisms and therapeutic targets to protect against these diseases. 
 As we learn more about neovascularization, we will continue to develop and 
explore new animal models for the treatment and prevention of disease. This short 
review is not a comprehensive study on all the available mouse models for preclinical 
testing, but it summarizes signiﬁ cant trends and variability in RNV research and the 
high impact mouse models have in human disease studies. Mouse models are crucial 
to understanding the molecular and cellular mechanism behind retinal degeneration 
and will continue to provide avenues for potential therapeutic advancement. 
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